Early Bird Registration Deadline for the ICNC has been extended toJULY 15, 2022
The objectives of this symposium on opsoclonus-myoclonusataxia syndrome (OMAS) are to provide participants with up-todate consensus opinions from a collaborative international OMAS study group. Attendees will learn current epidemiology, diagnostic criteria, biological mechanisms of disease, optimal treatment, and long-term outcomes.
Learning Objectives 1. Explain cardinal presenting features, ratings scales, and the clinical course of opsoclonusmyoclonus-ataxia syndrome (OMAS). 2. Apply common evaluation and treatment practices for patients with OMAS.
- The recognition and initial evaluation of children with opsoclonus-myoclonus-ataxia syndrome.
- The use of immunomodulatory agents in the early course of and long-term follow-up of opsoclonus-myoclonus-ataxia syndrome.
Tim Lotze, MD
Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas, USA
Cardinal Presenting Features, Rating Scales, and the Clinical Course of OpsoclonusMyoclonus-Ataxia Syndrome
Ming Lim, MD, PhD
Evelina London Children’s Hospital, King’s Health Partners Academic Health Science Centre, London, United Kingdom
Recognized Etiologies and Emerging Biomarkers in Opsoclonus-Myoclonus- Ataxia Syndrome
Russell Dale, MRCP, PhD
Children’s Hospital at Westmead, University of Sydney, Sydney, NSW, Australia
Consensus Recommendations for the Evaluation and Treatment of Opsoclonus-MyoclonusAtaxia Syndrome
Mark Gorman, MD
Boston Children’s Hospital, Boston, Massachusetts, USA
Short and Long-term Neurodevelopmental Outcomes in Opsoclonus-Myoclonus- Ataxia Syndrome
Wendy G. Mitchell MD
Keck School of Medicine, Children’s Hospital Los Angeles, Los Angeles, California, USA